OmniAb (NASDAQ:OABI) Announces Earnings Results, Misses Estimates By $0.03 EPS

OmniAb (NASDAQ:OABI) announced its quarterly earnings data on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03), FiscalAI reports. OmniAb had a negative return on equity of 23.90% and a negative net margin of 347.04%.The firm had revenue of $8.38 million for the quarter, compared to analysts’ expectations of $9.00 million.

Here are the key takeaways from OmniAb’s conference call:

• OmniAb ended 2025 with 107 partners and 407 active programs, stating that >98% of active programs have contracted future economics totaling approximately $3 billion in milestone payments and an average royalty of 3.4%.
• Management launched two new platform growth drivers — OmniUltra (transgenic chicken platform producing ultra‑long CDRH3s that enable picobodies and peptide opportunities) and xPloration (high‑throughput single B‑cell instrument + consumables + software) — and reported 2 xPloration systems deployed with strong partner interest.
• Program advancement picked up in 2025 with 25 progression events (including discovery→preclinical and preclinical→phase 1), one program reaching registration stage, and the first OmnidAb‑derived program entering human trials within two years of platform launch; clinical programs have ~$350 million of remaining contracted milestones.
• Financials were weaker year‑over‑year — 2025 revenue of $18.7 million (down from $26.4M) and a FY net loss of $64.8 million — management guides 2026 revenue of $25–30 million, operating expense of $80–85 million, and expects year‑end cash of $30–35 million while saying they are on a trajectory to cash‑flow positivity but without a firm timeline.

OmniAb Price Performance

NASDAQ:OABI traded down $0.11 during midday trading on Friday, reaching $1.90. The stock had a trading volume of 34,453 shares, compared to its average volume of 347,417. The stock has a market capitalization of $272.80 million, a P/E ratio of -3.32 and a beta of 0.13. OmniAb has a 1-year low of $1.22 and a 1-year high of $3.45. The firm’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $1.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of OmniAb in a research note on Monday, December 22nd. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.67.

Insider Transactions at OmniAb

In other OmniAb news, CFO Kurt A. Gustafson sold 23,922 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $1.96, for a total transaction of $46,887.12. Following the completion of the sale, the chief financial officer directly owned 252,688 shares in the company, valued at $495,268.48. This represents a 8.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Matthew W. Foehr sold 30,843 shares of OmniAb stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.71, for a total value of $52,741.53. Following the completion of the transaction, the chief executive officer owned 4,403,277 shares in the company, valued at $7,529,603.67. The trade was a 0.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 130,021 shares of company stock valued at $233,398 over the last 90 days. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On OmniAb

Several hedge funds and other institutional investors have recently modified their holdings of OABI. AQR Capital Management LLC bought a new position in OmniAb during the first quarter worth $25,000. Osaic Holdings Inc. increased its holdings in shares of OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares during the period. BNP Paribas Financial Markets raised its position in shares of OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after buying an additional 10,438 shares during the last quarter. Cerity Partners LLC raised its position in shares of OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock valued at $39,000 after buying an additional 11,919 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of OmniAb in the fourth quarter valued at about $54,000. Institutional investors and hedge funds own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.